The transaction structure was not detailed; the amount is not equivalent to net new equity capital.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Oral dosage development combines spray-dried ASD, HME, particle size reduction, lipid formulations, and controlled release, spanning preclinical and clinical supply through commercial scale-up.
Program / service
Target / indication
Representative stage
Evidence & scope
Formulation development / contract manufacturing capabilities
Defined by the client project · Defined by the client project
Services / platform
Service pages do not establish human evidence for every project
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.
A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Available capacity, site-specific qualifications, project delivery history, pricing, and technology transfer terms require confirmation with the execution entity.
Company service pages support the stated scope but do not establish clinical validation of every dosage form or client program.
